CN113527248B - Xanthone compound and preparation method and application thereof - Google Patents

Xanthone compound and preparation method and application thereof Download PDF

Info

Publication number
CN113527248B
CN113527248B CN202110831774.9A CN202110831774A CN113527248B CN 113527248 B CN113527248 B CN 113527248B CN 202110831774 A CN202110831774 A CN 202110831774A CN 113527248 B CN113527248 B CN 113527248B
Authority
CN
China
Prior art keywords
crude
eluent
volume ratio
methanol
fermentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110831774.9A
Other languages
Chinese (zh)
Other versions
CN113527248A (en
Inventor
吴少华
鲁祎晗
刘思思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan University YNU
Original Assignee
Yunnan University YNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan University YNU filed Critical Yunnan University YNU
Priority to CN202110831774.9A priority Critical patent/CN113527248B/en
Publication of CN113527248A publication Critical patent/CN113527248A/en
Application granted granted Critical
Publication of CN113527248B publication Critical patent/CN113527248B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82Xanthenes
    • C07D311/84Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86Oxygen atoms, e.g. xanthones
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/14Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
    • A01N43/16Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Abstract

The invention provides xanthone compounds, which belong to the technical field of biological medicines, and comprise at least one of phosphops i xanthenes A-G, and the series of xanthone compounds can resist plant pathogenic fungi and have antioxidant activity, can be used for preparing agricultural antibacterial agents and antioxidant drugs, and have higher agricultural and medical commercial values. The invention also provides a preparation method and application of the xanthone compound.

Description

Xanthone compound and preparation method and application thereof
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a xanthone compound as well as a preparation method and application thereof.
Background
Xanthone compounds are an isotridecyl compound. It is an important organic synthesis intermediate, the parent body itself does not exist in the plant body, but the derivatives thereof widely exist in the nature, and the derivatives are collectively called as xanthone compounds and are one of the effective components of medicinal plants. These compounds have different biological activities mainly because of the different groups on their substituents. Due to their diverse and special structures, they are generally capable of exhibiting various biological activities of modulating body immunity, anti-tumor, and anti-inflammatory, and they are also important substances for developing novel antibiotics. At present, the main sources of natural extraction of xanthones are plants and microorganisms. In recent years, microorganisms have been considered as a major source of xanthones having important biological activities in the future, because of the relatively small amount of xanthones found in natural products of plant origin.
Disclosure of Invention
The invention aims to provide xanthone compounds, and the series of xanthone compounds can resist plant pathogenic fungi and have antioxidant activity, can be used for preparing agricultural antibacterial agents and antioxidant drugs, and have higher agricultural and medical commercial values.
The invention also provides a preparation method and application of the xanthone compound.
The invention is realized by the following technical scheme:
the invention provides xanthone compounds, which comprise at least one of phosphosixannes A-G, wherein the structural formulas of the phosphosixannes A-G are respectively shown as (I) to (VII):
Figure BDA0003175827260000011
based on the same inventive concept, the invention also provides a preparation method of the xanthone compound, which comprises the following steps:
fermenting phomopsis, and collecting fermentation liquor and mycelia after fermentation is finished;
extracting the fermentation liquor, leaching the mycelium, mixing extracting solutions, and volatilizing a solvent to obtain a fermentation crude extract;
carrying out chromatographic separation on the crude fermentation extract, eluting by adopting a chloroform-methanol system, and collecting crude components Fr.1-Fr.3;
subjecting the crude fraction Fr.1 to chromatographic separation with an eluent comprising petroleum ether-ethyl acetate to obtain the compounds phosphopsisaxanthone A, phosphopsisaxanthone B and phosphopsisaxanthone C;
subjecting the crude fraction Fr.2 to chromatographic separation, eluting with a methanol-water system to obtain phosphopsisaxanthone D and phosphopsisaxanthone E;
the crude fraction Fr.3 is chromatographed using chloroform-acetone as eluent to give the compounds phosphopsisaxanthone F and phosphopsisaxanthone G.
Optionally, the Phomopsis sp.YE3350 is a strain which has been preserved in China center for type culture Collection (CCTCC for short) at 8/3 of 2020, and the preservation number is CCTCC NO. M2020394. The preservation address is China, Wuhan and Wuhan university, and the taxonomy is named Phomopsis sp.
Optionally, the phomopsis is fermented, and fermentation liquor and mycelia are collected after fermentation is finished, and the method specifically comprises the following steps:
placing phomopsis into a PDB culture medium for fermentation, and collecting fermentation liquor and mycelia after the fermentation is finished, wherein the concentration of potatoes in the PDB culture medium is 0.2-0.4 g/mL, and the concentration of glucose in the PDB culture medium is 0.02-0.05 g/mL;
the PDB culture medium is prepared by the following method:
cutting 200-400 parts of peeled potatoes into pieces, adding 1000 parts of water, boiling and filtering to obtain a potato filtrate;
adding 20-50 parts of glucose, 3-5 parts of dipotassium hydrogen phosphate, 3-5 parts of magnesium sulfate and vitamin B into the potato filtrate10.01-0.03 part of PDB culture medium.
Optionally, the extracting the fermentation broth, leaching the mycelium, mixing the extracting solutions, and volatilizing the solvent to obtain a fermentation crude extract specifically includes:
extracting the fermentation liquor by using ethyl acetate, leaching the mycelium by using methanol, combining extracting solutions, and volatilizing a solvent to obtain a fermentation crude extract.
Optionally, the crude fermentation extract is subjected to chromatographic separation, an eluent adopts a chloroform-methanol system, and crude components fr.1-fr.3 are collected, and the method specifically comprises the following steps:
and (3) carrying out chromatographic separation on the fermented crude extract, carrying out gradient elution on the fermented crude extract by using an eluent in a chloroform-methanol system, wherein the volume ratio of chloroform to methanol is 95:5 to 1:1, collecting a crude component Fr.1 eluted when the volume ratio of chloroform to methanol is 95:5, collecting a crude component Fr.2 eluted when the volume ratio of chloroform to methanol is 9:1, and collecting a crude component Fr.3 eluted when the volume ratio of chloroform to methanol is 8: 2.
Alternatively, the crude fraction fr.1 is chromatographed using an eluent in the petroleum ether-ethyl acetate system to obtain the compounds phosphosiloxane a, phosphosiloxane B and phosphosiloxane C, including in particular:
carrying out chromatographic separation on the crude component Fr.1, carrying out gradient elution on the crude component Fr.1 by using an eluant through a petroleum ether-ethyl acetate system and using petroleum ether and ethyl acetate in a volume ratio of 95:5 to 6:4, collecting fractions eluted when the volume ratio of the petroleum ether to the ethyl acetate is 9:1, and volatilizing the eluant to obtain a xanthone compound phosphopsisaxanthone A; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 8:2, and volatilizing an eluent to obtain a xanthone compound phosphopsoxanthene B; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 7:3, and volatilizing the eluent to obtain the xanthone compound phosphopsoxanthine C.
Alternatively, the crude fraction fr.2 is chromatographed using a methanol-water system as eluent to give the compounds phosphopsin D and phosphopsin E, which specifically include:
carrying out chromatographic separation on the crude component Fr.2, carrying out gradient elution on the crude component Fr.2 by using an eluent in a methanol-water system and using methanol and water in a volume ratio of 1:1 to 4:1, collecting fractions eluted when the volume ratio of methanol and water is 6:4, and volatilizing the eluent to obtain a xanthone compound phosphopsanthone D; collecting fractions eluted when the volume ratio of methanol to water is 7:3, and volatilizing the eluent to obtain the xanthone compound phosphopsoxanthine E.
Alternatively, the crude fraction fr.3 is chromatographed using a chloroform-acetone system as eluent to give the compounds phosphopsin F and phosphopsin G, including:
carrying out chromatographic separation on the crude component Fr.3, carrying out gradient elution on the crude component Fr.3 by using a chloroform-acetone system as an eluent according to the volume ratio of 9:1 to 1:1, collecting fractions eluted when the volume ratio of chloroform to acetone is 8:2, and volatilizing the eluent to obtain a xanthone compound phosphopsisaxanthone F; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 7:3, and volatilizing the eluent to obtain the xanthone compound phosphopsoxanthine G.
Based on the same inventive concept, the invention also provides the application of the xanthone compound in preparing agricultural antibacterial agents and/or antioxidant drugs.
One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
1. the xanthone compounds provide seven novel xanthone compounds A-G, can resist phytopathogens and have antioxidant activity, provide a new choice for developing agricultural antibacterial agents and antioxidant drugs, and have high agricultural and medical commercial values.
2. The xanthone compound is prepared by fermenting the strain Phomopsis sp.YE3350, and the method has the advantages of short period, mild culture conditions, few byproducts, low cost, higher economic value, low cost, simple and convenient operation and easy large-scale production, and provides a new way for obtaining the xanthone compound from natural sources.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on the drawings without creative efforts.
FIG. 1 shows phosphopsisaxanthone A, a compound of the present invention1H-NMR spectrum;
FIG. 2 shows phosphopsisaxanthone A of the present invention13C-NMR and DEPT spectra;
FIG. 3 is a drawing showing phosphopsisaxanthone B compound of the present invention1H-NMR spectrum;
FIG. 4 shows phosphopsisaxanthone B compounds of the present invention13C-NMR and DEPT spectra;
FIG. 5 is a graphic representation of phosphopsisaxanthone C, a compound of the present invention1H-NMR spectrum;
FIG. 6 is a graphic representation of phosphopsisaxanthone C, a compound of the present invention13C-NMR and DEPT spectra;
FIG. 7 shows phosphopsisaxanthone D compounds of the present invention1H-NMR spectrum;
FIG. 8 shows phosphopsisaxanthone D compounds of the present invention13C-NMR and DEPT spectra;
FIG. 9 shows phosphopsisaxanthone E of the compound of the present invention1H-NMR spectrum;
FIG. 10 shows phosphopsisaxanthone E of the compound of the present invention13C-NMR and DEPT spectra;
FIG. 11 shows phosphopsisaxanthone F, a compound of the present invention1H-NMR spectrum;
FIG. 12 shows phosphopsisaxanthone F of the present invention13C-NMR and DEPT spectra;
FIG. 13 shows phosphopsisaxanthone G of the present invention1H-NMR spectrum;
FIG. 14 shows phosphopsisaxanthone G of the present invention13C-NMR and DEPT spectra;
FIG. 15 shows the structural formulae of phosphopsisaxanthenes A-G of xanthone compounds according to the present invention.
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are for the purpose of illustrating the invention and are not to be construed as limiting the invention.
Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.
Unless otherwise specifically stated, various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or can be prepared by existing methods.
The xanthone compounds of the present application will be described in detail with reference to examples and experimental data.
Example 1
Isolation and preparation of xanthone compounds phomopsis xanthones A-G
(1) Preparing a PDB culture medium: weighing 200g of peeled potato, cutting into small pieces, adding 1000mL of distilled water, boiling, filtering with gauze to obtain potato filtrate, adding 20g of glucose, adjusting pH to natural, and sterilizing at 121 ℃ for 30min to obtain the PDB culture medium for later use. Wherein the concentration of potato in the PDB culture medium is 0.2g/mL, and the concentration of glucose is 0.02 g/mL.
Preparing an improved PDB culture medium: weighing peeled potato 200g, cutting into small pieces, adding 1000mL distilled water, boiling, filtering with gauze to obtain potato filtrate, adding glucose 20g, dipotassium hydrogen phosphate 3g, magnesium sulfate 3g, and vitamin B1Sterilizing at 121 deg.C for 30min at pH of 10mg to obtain improved PDB culture medium. Wherein the concentration of potato in the modified PDB medium is 0.2g/mL, and the concentration of glucose is 0.02 g/mL.
(2) Inoculating Phomopsis sp.YE3350 strain into PDB culture medium, shake-culturing at 28 + -2 deg.C and 200r/min for 4d to obtain seed solution, inoculating the prepared seed solution into fermentation culture medium modified PDB culture medium according to 10% of inoculum size, shake-culturing at 28 + -2 deg.C and 200r/min for 7-9 d to obtain fermentation product.
(3) Filtering the fermentation product obtained in the step (2) by using gauze to obtain fermentation liquor and mycelium, extracting the fermentation liquor by using ethyl acetate, extracting the mycelium by using methanol, combining extracting solutions, and concentrating under reduced pressure to obtain a fermentation crude extract.
(4) Subjecting the fermented crude extract to chromatographic separation by using a silica gel column (200-300 meshes), carrying out gradient elution on the fermented crude extract by using a chloroform-methanol system from a volume ratio of 95:5 to 1:1, collecting a crude component Fr.1 eluted by using the chloroform-methanol system from the volume ratio of 95:5, collecting a crude component Fr.2 eluted by using the chloroform-methanol system from the volume ratio of 9:1, and collecting a crude component Fr.3 eluted by using the chloroform-methanol system from the volume ratio of 8: 2.
Gradient elution is carried out on the crude component Fr.1 from a volume ratio of 95:5 to 6:4 by a petroleum ether-ethyl acetate system, fractions obtained by elution when the volume ratio of petroleum ether to ethyl acetate is 9:1 are collected, and the xanthone compound phosphopsisaxanthone A can be prepared; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 8:2, and preparing a xanthone compound phosphopsoxanthene B; fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 7:3 are collected, and the xanthone compound phosphopsoxanthine C can be prepared.
Performing gradient elution on the crude component Fr.2 from 1:1 to 4:1 in a methanol-water system, and collecting fractions eluted when the volume ratio of methanol to water is 6:4 to prepare a xanthone compound phosphopsisaxanthone D; fractions eluted at a methanol-water volume ratio of 7:3 are collected to prepare the xanthone compound phosphopsoxanthine E.
Performing gradient elution on the crude component Fr.3 by using a chloroform-acetone system from a volume ratio of 9:1 to 1:1, and collecting fractions eluted when the chloroform-acetone volume ratio is 8:2 to prepare a xanthone compound phosphopsisaxanthone F; fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 7:3 are collected, and the xanthone compound phosphopsoxanthine G can be prepared.
Example 2
The results of structural identification of Phomopsis xanthones A to G are shown in FIG. 15.
Structure identification of xanthone compound phosphopsisxanthone A
The structure of the compound phosphopsisaxanthone A prepared in example 1 was identified by 1D/2D NMR (one-dimensional and two-dimensional nuclear magnetic resonance spectrum) and HRESI-MS (high resolution electrospray ionization mass spectrometry). Phomopsis xanthone A has a molecular formula of C15H12O5;HRESIMS m/z:271.0607[M-H]-The unsaturation degree was 10.
As shown in the figures 1 and 2, the above-mentioned figures,1the H-NMR spectrum showed a hydroxyl proton (. delta.)H13.00), one methyl proton (. delta.))H2.37), four methine protons (. delta.))H6.58,6.71,6.80,7.23), a methylene group (delta) linked to oxygenH5.07). According to its unsaturation of 10, there should be three benzene rings in addition to one carbonyl group.1H-1The H COSY spectrum shows two sets of meta-aromatic hydrogen protons, indicating the presence of two 1,2,3, 5-tetrasubstituted aromatic rings. From the HMQC spectrum, a peak at 12-OH (. delta.) can be observedH5.39) and 1-OH (. delta.))H12.94), also shows the methyl proton CH3-11(δH2.37) and the oxygen-bound hydroxyl proton CH2-12(δH5.07) correlation with C-11 and C-12, indicating CH3-11 and CH2-12 is linked to C-11, C-12, respectively. CH is observed in its HMBC profile3The correlation of-11 to C-1, C-2, C-4 indicates the presence of a methyl group at the C-3 position. Furthermore, the oxygen-linked proton CH is observed2The correlation of-12 with C-7, C-8 and C-8a indicates CH2The connection mode of OH and C-8. From the HMBC spectrum, delta can be seenHThe connection of 1-OH and C-1 can be determined from the correlation of the hydroxyl proton at position 12.94 with C-1, C-2, C-9 a. From HMBC and1H-1the H COSY map and the characteristics of meta substitution infer the connection of 6-OH and C-6, and further infer the correlation of 12-OH and methylene C-12. The compound 1 is xanthone compound, which is substituted by methyl and hydroxymethyl at C-3 and C-8Substituted at C-1 and C-6 with hydroxy groups, was searched as a novel compound, named phosphopsisaxanthone A, having the formula shown in the following formula (I):
Figure BDA0003175827260000061
structural identification of xanthone compound phomopsis xanthone B
The structure of the compound phosphopsisaxanthone B prepared in example 1 was identified by 1D/2D NMR (one-dimensional and two-dimensional nuclear magnetic resonance spectrum) and HRESI-MS (high resolution electrospray ionization mass spectrometry). Phomopsis xanthone B has the molecular formula of C15H12O5;HRESIMS m/z 271.0506[M-H]-The unsaturation degree was 10.
As shown in fig. 3 and 4, compared with the compound phosphopsisaxanthone a,1the H-NMR spectrum is shown at deltaHThe presence of two low field shifted aromatic proton signals at 7.46 and 7.40, both of which were calculated to have coupling constants of 9.1Hz, indicates the presence of ortho substitution on the benzene ring of the compound. By comparison1H-1Comparison of the H COSY, HMBC and HMQC spectra reveals that the compound phosphosiloxane A is identical to the compound phosphosiloxane B in both ring A and ring B and that meta substitution is present. From the HMBC profile H-2 (. delta.) can be observedH 6.61),H-4(δH6.83) and the methyl carbon C-11 (. delta.))C22.4) there is a correlation point, indicating the attachment of C-11 to C-3. C-8 (delta)C 125.7),C-6(δC 125.6),C-12(δC55.8) displacement to low electric field, C-5 (. delta.)C 111.8),C-7(δC152.7) to a high electric field, indicating that the hydroxyl protons are at the C-7 position and are affected by 7-OH, so that their chemical shifts change. In combination with the above analysis, the compound phosphopsisaxanthone A was determined to be a xanthone. Substituted at C-3 and C-8 with methyl and one hydroxymethyl group, respectively, and at C-1 and C-7 with hydroxy, was searched as a novel compound, named phosphosiloxane B, having the formula shown in the following formula (II):
Figure BDA0003175827260000071
structural identification of xanthone compound phomopsis xanthone C
The structure of the compound phosphopsisaxanthone C prepared in example 1 was identified by 1D/2D NMR (one-dimensional and two-dimensional nuclear magnetic resonance spectrum) and HRESI-MS (high resolution electrospray ionization mass spectrometry). The molecular formula of Phomopsis xanthone C is C15H12O5;HRESIMS m/z 271.0607[M-H]-The unsaturation degree was 10.
As shown in FIGS. 5 and 6, the hydrogen spectrum and carbon spectrum of the compound have one more methoxy group (. delta.) than that of the compound phosphopsisaxanthone AH4.04;δC62.8), one methylene group less.1The H-NMR spectrum is shown at deltaH7.46 and deltaHAt 7.40 there are two low field shifted aromatic proton signals, both of which have a coupling constant of 8.8Hz, indicating ortho-substituted benzene rings. From it1H-1A group of methine protons (delta) can be seen in the H COSY spectrumH 6.69;δH6.60), we conclude that there is a meta substitution on the phenyl ring. From the HMBC spectrum, the hydroxyl proton 6-OH (. delta.) can be observedH5.97) and C-5 (. delta.))C 118.8),C-6(δC 125.6),C-7(δC152.7) has a correlation, which determines the linkage of the hydroxyl proton 6-OH to C-6. The connection of the A and B rings of the compound phosphopsisaxanthone C was determined in the same manner as the compound phosphopsisaxanthone A. The above analysis was combined to determine that the compound phosphopsisaxanthone C also belongs to xanthones, is substituted at C-3 and C-5 with methyl and methoxy groups, respectively, and at C-1 and C-6 with hydroxy groups, and was searched for a new compound, designated phosphopsisaxanthone C, having the formula shown in the following formula (III):
Figure BDA0003175827260000081
structural identification of xanthone compound phomopsis xanthone D
The compound phomop prepared in example 1sisxanthone D, whose structure was identified by 1D/2D NMR (one-dimensional and two-dimensional nuclear magnetic resonance spectroscopy) and HRESI-MS (high resolution electrospray ionization mass spectrometry). Phomopsis xanthone D has a molecular formula of C15H12O4;HRESIMS m/z 257.0806[M-H]-The unsaturation degree was 10.
Referring to FIGS. 7 and 8, the spectra of this compound show one less hydroxyl proton and 16 less molecular weight than the phosphopsinanthone A compound. Combining the comparison results of hydrogen spectrum and carbon spectrum, the compound phosphopsisaxanthone A is judged to be in deltaH7.65 has more signal peaks and is an aromatic methine. From the HMBC spectra, proton H-6 (. delta.) was observedH7.65) and C-10a (. delta.))C157.9) and C-8 (. delta.))C142.7) has remote correlation.1H-1The H COSY spectrum can observe the existence of a 2,3, 4-substituted ring in addition to a meta-substituted ring. From the one-dimensional two-dimensional spectrum of nuclear magnetic resonance, it was confirmed that the A ring and the B ring were linked in the same manner as the compound phosphosiloxane A without substitution of the hydroxyl group at the C-6 position of the C ring. The above analysis was combined to determine that the compound phosphopsisaxanthone D is a xanthone compound in which C-3 and C-8 are substituted with methyl and hydroxymethyl groups, respectively, and which is substituted with a hydroxyl group at C-1. The compound is named phosphopsisaxanthone D through searching, and the structural formula of the compound is shown as the following formula (IV):
Figure BDA0003175827260000082
structural identification of xanthone compound phomopsis xanthone E
The structure of the compound phosphopsisaxanthone E prepared in example 1 was identified by 1D/2D NMR (one-dimensional nuclear magnetic resonance spectrum and two-dimensional nuclear magnetic resonance spectrum) and HRESI-MS (high resolution electrospray ionization mass spectrometry). Phomopsis xanthone E has a molecular formula of C15H12O4;HRESIMS m/z:311.0529[M-H]-The unsaturation degree was 10.
As shown in FIGS. 9 and 10, the pattern data of the compound is one more methylene even oxygen compared with the compound phosphopsoxanthine AOne less methyl group. According to which1As a result of the H-NMR spectrum display, it can be seen that the difference in the value of deltaH7.50 and deltaHAt 7.41 there are low electric field displaced aromatic proton signals with the same coupling constant of 9.12Hz, and we conclude that ortho substitution may occur on the benzene ring. At deltaH6.95 and deltaHAt 6.72 there is a pair of aromatic proton signals, consisting of1H-1The H COSY spectrum confirms that a group of meta-substituted aromatic protons exist on the benzene ring. From HMBC spectra, methine CH can be observed2-11(δH4.58) and C-4 (. delta.))C 103.9),C-2(δC107.4), and C-3 (. delta.))C154.0) there is a correlation, confirming CH2-11 and C-3. Furthermore, the oxygen-linked proton CH is observed2-12(δH5.12) and C-7 (. delta.)C152.7),C-8(δC127.4) and C-8a (. delta.))C119.1), which also indicates CH2The connection mode of OH and C-8. From the HMQC spectrum, 11-OH and CH can be observed2-11 and 12-OH and CH2The existence of a point with correlation of-12 determines the connection mode of two continuous oxygen methylene groups. In summary, the compound phosphopsisaxanthone E was determined to be a xanthone. Substituted by hydroxymethyl at C-3 and C-8, respectively, and substituted by hydroxyl at C-1, respectively, and is searched to be a new compound, namely phosphopsoxanthine E, the structural formula of which is shown as the following formula (V):
Figure BDA0003175827260000091
structural identification of xanthone compound phomopsis xanthone F
The structure of the compound phosphopsisaxanthone F prepared in example 1 was identified by 1D/2D NMR (one-dimensional nuclear magnetic resonance spectrum and two-dimensional nuclear magnetic resonance spectrum) and HRESI-MS (high resolution electrospray ionization mass spectrometry). Phomopsis xanthone F has a molecular formula of C15H12O5;HRESIMS m/z:271.0607[M-H]-The unsaturation degree was 10.
The compounds and the compounds phomopsis are shown in figures 11 and 12Compared with xanthone A, one more hydroxymethyl group (delta)H4.69;δC62.9) and methine (. delta.) groupsH 7.70;δC137.5) with one less methyl group. The formula is the same as that of the compound phosphosiloxane A, indicating that the position of the methylene group attachment has changed. From1H-1The H COSY spectrum can observe that a 2,3, 4-substituted ring exists in addition to a group of meta-substituted rings. In a two-dimensional HMBC map, methylene CH is shown2-11(δH4.68) and quaternary carbon C-5 (. delta.)C 113.2),C-6(δC152.1) and C-7 (. delta.))C119.6) shows a correlation between methine CH2The-11 linkage is at the C-6 position. CH (CH)2-12(δH5.44) with C-7, C-8 and C-8a (. delta.)C115.7) are all present, the CH is determined2-12 is attached at the position of C-12. Based on the two substituted rings and the above data, it was determined that 12-OH, 11-OH is attached to C-12 and C-11, respectively. The compound phosphopsisaxanthone F, which has a hydroxymethyl substitution at both the C-6 and C-8 positions and a hydroxyl substitution at C-1, was searched for as a novel compound, designated phosphopsisaxanthone F, and its formula is shown in formula (VI):
Figure BDA0003175827260000101
structural identification of xanthone compound phosphopsisxanthone G
The structure of the compound phosphopsisaxanthone G prepared in example 1 was identified by 1D/2D NMR (one-dimensional nuclear magnetic resonance spectrum and two-dimensional nuclear magnetic resonance spectrum). Phomopsis xanthone G has a molecular formula of C15H10O6(ii) a The unsaturation degree was 11.
Referring to FIGS. 13 and 14, the compound phosphopsisaxanthone G was identified as xanthone by comparing the data of one-dimensional and two-dimensional nuclear magnetic resonance of the compound phosphopsisaxanthone G with that of the compound phosphopsisaxanthone A. Compound phosphopsin G has one more carboxyl group (. delta.) than compound phosphopsin AC168.7) one less methyl and one less hydroxyl group and relative molecular massThe amount was 14 more. From the HMBC profile, H-5 (. delta.) (H 8.33),H-7(δH9.27) methine proton and carboxyl group C-11 (. delta.))C168.7) indicating the attachment of C-11 and C-6. Taken together, the compound phosphosiloxane G, which has a hydroxyl substitution at C-1 and a carboxyl and hydroxymethyl substitution at C-6 and C-8, respectively, was searched for a new compound, designated phosphosiloxane G, having the formula (VII):
Figure BDA0003175827260000102
the seven xanthones described in this example are all white amorphous powders, which are soluble in methanol, pyridine, dimethyl sulfoxide, etc., and insoluble in petroleum ether and water. Process for preparation of phosphopsisaxanthones A-G1The H NMR data are shown in Table 1,13the CNMR data are shown in Table 2.
TABLE 1 preparation of xanthones A-G1H NMR data
Figure BDA0003175827260000103
Figure BDA0003175827260000111
The determination solvent of Phomopsis xanthone A and B, F is deuterated dimethyl sulfoxide; the determination solvent of phosphopsisaxanthone C and phosphopsoxanthine D is deuterated chloroform; the solvent for phosphopsisaxanthone E, G assay was deuterated pyridine.
TABLE 2 method for preparation of phosphasixanthones A to G13C NMR data
Figure BDA0003175827260000112
Figure BDA0003175827260000121
Example 3
Determination of anti-phytopathogen activity and anti-oxidation activity of xanthone compounds A to G:
(1) and (3) activity determination of anti-phytopathogen:
the 4 plant pathogen indicator bacteria include Botrytis cinerea (Botrytis cinerea), Gibberella cerevisi (Gibberella sautiniii), Fusarium solani (Fusarium solani), and Curvularia lunata (Curvularia lunata). The culture medium is PDB culture medium.
Under sterile conditions, well-growing pathogens were inoculated into 250mL Erlenmeyer flasks containing 100mL of liquid medium per flask. 1024. mu.g of the compound was weighed, dissolved in DMSO solution, and diluted to 516-2. mu.g/mL on a 96-well plate with sterile water at a double ratio. Add 50. mu.L of bacterial suspension to each well, pipette and mix well. The positive control is nystatin, 2 groups of pathogenic bacteria are subjected to parallel experiments, the pathogenic bacteria are cultured for 24-48h at 28 ℃, and the result is observed and recorded once every 8 h.
(2) DPPH radical scavenging capacity:
weigh 1mg of sample to be tested, add 2mL of DMSO to dissolve to obtain 0.5mg/mL of sample stock solution. Then, the prepared mother liquor is diluted to 5-50 mu g/mL. 7.886mg of DPPH (1, 1-diphenyl-2-trinitrophenylhydrazine) was weighed out and dissolved in 100mL of DMSO solution to give a 0.2mM DPPH stock solution. 1mL of the prepared DPPH mother solution was added to compound solutions of different concentrations (3mL, 5-50. mu.g/mL) and reacted for 30 minutes in the dark. The reacted sample (200. mu.L) was put in a 96-well plate, and the absorbance at 517nm was measured with a microplate reader. DMSO as negative control, vitamin C (V)C) And vitamin E (V)E) Is a positive control.
The measured data are expressed by the formula [ (Ac-As)/Ac]X 100% DPPH radical clearance K (%) of the compounds was calculated, respectively. Ac is the absorbance of the negative control DMSO at 517nm, As is the added compound or the positive control VCAnd VEAbsorbance measured at 517 nm. Calculating the IC of the compound from its free clearance data50(median inhibitory concentration) value.
(3)ABTS+Radical scavenging ability:
1mg of a sample to be tested is weighed and dissolved in 2mL of DMSO to obtain a sample mother solution of 0.5 mg/mL. Then, the prepared mother liquor is diluted to 5-50 mu g/mL. Weighing 109.736mg ABTS+(2, 2-Aza-bis (3-ethyl-benzothiazole-6-sulfonic acid) diammonium salt) and 66.2284mg of potassium persulfate were dissolved in 100mL of water and reacted at room temperature in the dark for 12 hours to obtain ABTS+The mother liquor was at a concentration of 0.2 mM. Absorb 1mL of configured ABTS+The mother liquor was added to a diluted solution of the compound of different concentrations (3mL,5-50g/mL) and reacted for 10 minutes under dark conditions. 200. mu.L of the reacted sample was placed in a 96-well plate, and the absorbance at 734nm was measured using a microplate reader. DMSO was a negative control in this assay, VCAnd VEIs a positive control. The measured data are expressed by the formula [ (Ac-As)/Ac]100% DPPH radical scavenging ratio K (%) of the respective compounds was calculated. Ac is the absorbance of the negative control DMSO at 517nm, As is the added compound or the positive control VCAnd VEAbsorbance measured at 734 nm. Calculating the IC of the compound from its free clearance data50The value is obtained.
The Minimum Inhibitory Concentration (MIC) values of xanthone compounds A to G produced by the endophytic fungi Phomopsis sp.YE3350 of the present invention against 4 plant pathogenic bacteria are shown in Table 3.
TABLE 3 inhibitory Activity of the compounds phomopsis xanthones A-G against 4 plant pathogenic fungi
Figure BDA0003175827260000131
Phomopsis xanthones A-G generated by endophytic fungus Phomopsis sp.YE3350 of the invention can remove DPPH free radical and ABTS+Half maximal Inhibitory Concentration (IC) of free radicals50) As shown in table 4.
TABLE 4 free radical scavenging Activity of the Compounds Phomopsis xanthones A-G
Figure BDA0003175827260000132
Experimental results show that the xanthone compounds phosphopsisaxanthones A-G of the invention all show antibacterial activities of different degrees to 4 plant pathogen indicator bacteria, wherein the compounds have stronger inhibition effect on wheat scab, and especially the MIC values of the compounds phosphopsisaxanthone B and phosphopsisaxanthone G to wheat scab are only 2 mug/mL. Among the compounds tested, phosphoissanthone A showed the strongest inhibitory effect on Fusarium solani with MIC values of 4. mu.g/mL, phosphoissanthone E and phosphoissanthone G showed the strongest inhibitory activity on Botrytis cinerea with MIC values of 4. mu.g/mL. In the antioxidant activity experiment, xanthone compounds phosphopsixanthone A-G show different degrees of free radical scavenging ability, and particularly, the compounds phosphopsixanthone D, phosphopsixanthone E and phosphopsixanthone G have stronger activity, which indicates that the compounds have stronger antioxidant ability. In conclusion, the xanthone compounds phosphopsisaxanthenes A-G have potential application in preparing novel agricultural antibacterial agents and antioxidant drugs.
One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
(1) in the process of preparing the crude fermentation extract, the fermentation liquor is extracted by ethyl acetate, and the mycelium is leached by methanol, so that the effective components in the fermentation liquor and the mycelium are extracted, and the method has the advantage of separating the effective substances in the fermentation product from the unused culture medium components and water-soluble impurities.
(2) According to the preparation method of xanthone compounds, the improved PDB culture medium is adopted as the fermentation culture medium of phomopsis, compared with the conventional PDB culture medium, the method has the beneficial effect that fermentation products different from the conventional PDB culture medium can be generated, and the synthesis of microbial fermentation products can be influenced due to the change of the components of the culture medium.
(3) In the process of collecting crude components Fr.1-Fr.3 and separating phospho-isoxanthones A-G, the method for preparing the xanthone compounds aims to obtain corresponding target fractions or target products by selecting different eluent systems and different volume ratios of the eluents, and if other eluent systems or other volume ratios are adopted, the separation process for obtaining the target products phospho-isoxanthones A-G is more complicated, takes longer time or is difficult to obtain than the prior art.
Finally, it should also be noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.

Claims (7)

1. The application of Phomopsis sp.YE3350 in preparing xanthone compounds is characterized in that the Phomopsis sp.YE3350 is preserved in China center for type culture collection (CCTCC NO.M 2020394) at 8/3 in 2020;
the xanthone compound is prepared by fermenting Phomopsis sp.YE3350 of Phomopsis;
the xanthone compound comprises at least one of phosphopsisaxanthones A-G, and the structural formulas of the phosphopsisaxanthones A-G are respectively shown as (I) to (VII):
Figure FDA0003670000010000011
the preparation method of the xanthone compound comprises the following steps:
fermenting Phomopsis sp.YE3350, and collecting fermentation liquid and mycelium after fermentation;
extracting the fermentation liquor, leaching the mycelium, combining extracting solutions, and volatilizing a solvent to obtain a fermentation crude extract;
carrying out chromatographic separation on the crude fermentation extract, eluting by adopting a chloroform-methanol system, and collecting crude components Fr.1-Fr.3;
subjecting the crude fraction Fr.1 to chromatographic separation with an eluent comprising petroleum ether-ethyl acetate to obtain the compounds phosphopsisaxanthone A, phosphopsisaxanthone B and phosphopsisaxanthone C;
subjecting the crude fraction Fr.2 to chromatographic separation, eluting with a methanol-water system to obtain phosphopsisaxanthone D and phosphopsisaxanthone E;
the crude fraction Fr.3 is chromatographed using chloroform-acetone as eluent to give the compounds phosphopsisaxanthone F and phosphopsisaxanthone G.
2. The application of claim 1, wherein the Phomopsis sp.YE3350 is fermented, and the fermentation broth and mycelium are collected after the fermentation is finished, and the method specifically comprises the following steps:
placing Phomopsis sp.YE3350 into a PDB culture medium for fermentation, and collecting fermentation liquor and mycelia after the fermentation is finished, wherein the concentration of potatoes in the PDB culture medium is 0.2-0.4 g/mL, and the concentration of glucose in the PDB culture medium is 0.02-0.05 g/mL;
the PDB culture medium is prepared by the following method:
cutting 200-400 parts of peeled potatoes into pieces, adding 1000 parts of water, boiling and filtering to obtain a potato filtrate;
adding to the potato filtrate20-50 parts of glucose, 3-5 parts of dipotassium hydrogen phosphate, 3-5 parts of magnesium sulfate and vitamin B10.01-0.03 parts of PDB culture medium.
3. The use according to claim 1, wherein the extracting of the fermentation broth, the leaching of the mycelium, the combining of the extracts, and the evaporation of the solvent, to obtain a fermentation crude extract, specifically comprises:
extracting the fermentation liquor by using ethyl acetate, leaching the mycelium by using methanol, combining extracting solutions, and volatilizing a solvent to obtain a fermentation crude extract.
4. The application of claim 1, wherein the crude fermentation extract is subjected to chromatographic separation, an eluent adopts a chloroform-methanol system, and crude components Fr.1-Fr.3 are collected, and the method specifically comprises the following steps:
and (3) carrying out chromatographic separation on the fermented crude extract, carrying out gradient elution on the fermented crude extract by using an eluent in a chloroform-methanol system, wherein the volume ratio of chloroform to methanol is 95:5 to 1:1, collecting a crude component Fr.1 eluted when the volume ratio of chloroform to methanol is 95:5, collecting a crude component Fr.2 eluted when the volume ratio of chloroform to methanol is 9:1, and collecting a crude component Fr.3 eluted when the volume ratio of chloroform to methanol is 8: 2.
5. Use according to claim 1, characterized in that the crude fraction fr.1 is chromatographed using an eluent in the petroleum ether-ethyl acetate system to obtain the compounds phosphosiloxane a, phosphosiloxane B and phosphosiloxane C, comprising in particular:
carrying out chromatographic separation on the crude component Fr.1, carrying out gradient elution on the crude component Fr.1 by using an eluant through a petroleum ether-ethyl acetate system and using petroleum ether and ethyl acetate in a volume ratio of 95:5 to 6:4, collecting fractions eluted when the volume ratio of the petroleum ether to the ethyl acetate is 9:1, and volatilizing the eluant to obtain a xanthone compound phosphopsisaxanthone A; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 8:2, and volatilizing an eluent to obtain a xanthone compound phosphopsoxanthene B; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 7:3, and volatilizing the eluent to obtain the xanthone compound phosphopsoxanthine C.
6. Use according to claim 1, wherein the crude fraction fr.2 is chromatographed using an eluent in the methanol-water system to give the compounds phosphopsin D and E, comprising in particular:
carrying out chromatographic separation on the crude component Fr.2, carrying out gradient elution on the crude component Fr.2 by using an eluent in a methanol-water system and using methanol and water in a volume ratio of 1:1 to 4:1, collecting fractions eluted when the volume ratio of methanol and water is 6:4, and volatilizing the eluent to obtain a xanthone compound phosphopsanthone D; collecting fractions eluted when the volume ratio of methanol to water is 7:3, and volatilizing the eluent to obtain the xanthone compound phosphopsixanthone E.
7. Use according to claim 1, wherein the crude fraction fr.3 is chromatographed using a chloroform-acetone system as eluent to give the compounds phosphopsin F and G, in particular comprising:
carrying out chromatographic separation on the crude component Fr.3, carrying out gradient elution on the crude component Fr.3 by using a chloroform-acetone system as an eluent according to the volume ratio of 9:1 to 1:1, collecting fractions eluted when the volume ratio of chloroform to acetone is 8:2, and volatilizing the eluent to obtain a xanthone compound phosphopsisaxanthone F; collecting fractions eluted when the volume ratio of petroleum ether to ethyl acetate is 7:3, and volatilizing the eluent to obtain the xanthone compound phosphopsoxanthine G.
CN202110831774.9A 2021-07-22 2021-07-22 Xanthone compound and preparation method and application thereof Active CN113527248B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110831774.9A CN113527248B (en) 2021-07-22 2021-07-22 Xanthone compound and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110831774.9A CN113527248B (en) 2021-07-22 2021-07-22 Xanthone compound and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113527248A CN113527248A (en) 2021-10-22
CN113527248B true CN113527248B (en) 2022-07-08

Family

ID=78120484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110831774.9A Active CN113527248B (en) 2021-07-22 2021-07-22 Xanthone compound and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113527248B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113481105B (en) * 2021-07-22 2022-05-17 云南大学 Novel phomopsis fungus strain, preparation method and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103597071A (en) * 2011-01-07 2014-02-19 埃尔舍利克斯治疗公司 Chemosensory receptor ligand-based therapies
CN103880808A (en) * 2013-10-16 2014-06-25 云南大学 Xanthone compounds and applications thereof
CN110951620A (en) * 2019-11-12 2020-04-03 中国科学院微生物研究所 Compound for resisting activity of helicobacter pylori, preparation method and application thereof
CN113481105A (en) * 2021-07-22 2021-10-08 云南大学 Novel phomopsis fungus strain, preparation method and application
CN113637010A (en) * 2021-07-22 2021-11-12 云南大学 Hydrogenated xanthone derivative and preparation method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103597071A (en) * 2011-01-07 2014-02-19 埃尔舍利克斯治疗公司 Chemosensory receptor ligand-based therapies
CN103880808A (en) * 2013-10-16 2014-06-25 云南大学 Xanthone compounds and applications thereof
CN110951620A (en) * 2019-11-12 2020-04-03 中国科学院微生物研究所 Compound for resisting activity of helicobacter pylori, preparation method and application thereof
CN113481105A (en) * 2021-07-22 2021-10-08 云南大学 Novel phomopsis fungus strain, preparation method and application
CN113637010A (en) * 2021-07-22 2021-11-12 云南大学 Hydrogenated xanthone derivative and preparation method and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Isolation of Xanthones from the Fermentation Products of the Endophytic Fungus of Phomopsis amygdale;Lin Yuan,等;《Chemistry of Natural Compounds》;20150531;第51卷(第3期);第460页化合物结构式,第461页第1段,第462页第4-5段 *
Sesquiterpene and Xanthone Derivatives from the Sea Fan-Derived Fungus Aspergillus sydowii PSU-F154;Kongkiat Trisuwan,等;《JOURNAL OF NATURAL PRODUCTS》;20110630(第74期);第1663-1667页 *
印楝植物内生真菌Phomopsis sp.的代谢产物研究;吴少华,等;《天然产物研究与开发》;20081215(第06期);第69-70+85页 *
海洋来源Phomopsis sp.属真菌天然产物研究进展;刘春鑫,等;《广东化工》;20171115(第21期);第102-104+123页 *
红树林微生物抗菌活性成分研究进展;徐志勇,等;《中国抗生素杂志》;20170430(第04期);第7-20页 *

Also Published As

Publication number Publication date
CN113527248A (en) 2021-10-22

Similar Documents

Publication Publication Date Title
CN113637010B (en) Hydrogenated xanthone derivative and preparation method and application thereof
Pittayakhajonwut et al. An anti-herpes simplex virus-type 1 agent from Xylaria mellisii (BCC 1005)
CN113527248B (en) Xanthone compound and preparation method and application thereof
CN109336873B (en) Compound lithocarolsA-F, preparation method thereof and application thereof in preparation of antitumor drugs
Luo et al. Biotransformation of bavachinin by three fungal cell cultures
Wang et al. Bioactive metabolites from Penicillium sp., an endophytic fungus residing in Hopea hainanensis
CN101928270B (en) Isobenzofuranone compound, preparation method thereof and use thereof
CN102977082B (en) Isocoumarin compound as well as preparation method and application thereof
CN111559999B (en) Lactone compound and extraction method and application thereof
CN102154125B (en) Phoma strain and application thereof
CN110283053A (en) A kind of symbiotic effects monomeric compound quick separating preparation method and application
Daferner et al. Strobilurin M, tetrachloropyrocatechol and tetrachloropyrocatechol methyl ether: new antibiotics from a Mycena species
CN117362366B (en) Clostridin diterpenoid compound and preparation method and application thereof
CN104059038B (en) A kind of sesquiterpenoids and application thereof
CN101805385A (en) Neoflavonoid compounds separated and purified from Tridax procumbens and preparation method thereof
CN101265248B (en) Cembrene lactone type diterpenoid lobophilides A and B, and preparation method and use thereof
CN113004237A (en) Spiro compound and preparation method and application thereof
CN100465188C (en) Novel antibiotic Chemomycin A, B, C, D and preparation method thereof
CN112294781A (en) Application of butyrolactone metabolic ketone I in preparation of antitumor drugs
CN1243823C (en) Amycolatosis and biological conversion of lovastatin into wuxistatin thereby
CN114213428B (en) Indole alkaloid compound and preparation method and application thereof
CN111574362B (en) Fatty acid compound
CN115650854B (en) Integrin derivative, its preparation method and application in alpha-glucosidase inhibiting medicine
CN111072619B (en) Compound with drug-resistant bacterium resisting effect and preparation method and application thereof
CN103333176B (en) Norlignan compounds and method of separating and verifying norlignan compounds from pouzolzia zeylanica var. microphylla

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant